Edition:
India

Seres Therapeutics Inc (MCRB.OQ)

MCRB.OQ on NASDAQ Stock Exchange Global Select Market

2.61USD
18 Jun 2019
Change (% chg)

-- (--)
Prev Close
$2.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
100,439
52-wk High
$9.75
52-wk Low
$2.02

Latest Key Developments (Source: Significant Developments)

Seres Therapeutics Announces Pricing Of Public Offering Of Common Stock
Friday, 14 Jun 2019 

June 13 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SERES THERAPEUTICS - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 26,666,667 SHARES OF ITS COMMON STOCK, AT A PUBLIC OFFERING PRICE OF $2.25 PER SHARE.  Full Article

Seres Therapeutics Reports First Quarter Financial Results And Provides Clinical Pipeline Progress Update
Thursday, 2 May 2019 

May 2 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CLINICAL PIPELINE PROGRESS UPDATE.SERES THERAPEUTICS INC - FOUR SIGNIFICANT MICROBIOME PROGRAM MILESTONES EXPECTED DURING 2020, INCLUDING READOUTS FROM TWO LATE-STAGE DEVELOPMENT PROGRAMS.SERES THERAPEUTICS INC - EXPECTS TO FILE AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION AND INITIATE CLINICAL DEVELOPMENT FOR SER-301 IN EARLY 2020..SERES THERAPEUTICS INC - EXPECTS TO OBTAIN SER-401 PHASE 1B PRELIMINARY STUDY RESULTS IN 2020.SERES THERAPEUTICS INC - CASH RESOURCES ARE EXPECTED TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO Q4 OF 2019..SERES THERAPEUTICS INC - QTRLY NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS $0.59.  Full Article

Seres Therapeutics Announces Corporate Changes To Focus On Advancing Clinical Assets
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS ANNOUNCES CORPORATE CHANGES TO FOCUS ON ADVANCING CLINICAL ASSETS.SERES THERAPEUTICS INC - COMPANY WILL NOW CONCENTRATE ON COMPLETING RECENTLY-INITIATED SER-287 PHASE 2B STUDY IN MILD-TO-MODERATE ULCERATIVE COLITIS.SERES THERAPEUTICS INC - WILL MAKE CHANGES TO ITS EXECUTIVE TEAM AND REDUCE ITS FULL-TIME WORKFORCE BY APPROXIMATELY 30 EMPLOYEES.  Full Article

Seres Therapeutics Appoints Eric Shaff As Chief Executive Officer
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS ANNOUNCES CHIEF EXECUTIVE OFFICER TRANSITION.SERES THERAPEUTICS INC - ROGER J. POMERANTZ, M.D., TO CONTINUE TO SERVE AS CHAIRMAN.SERES THERAPEUTICS INC - ERIC SHAFF, PREVIOUSLY CHIEF OPERATING AND FINANCIAL OFFICER, APPOINTED PRESIDENT AND CHIEF EXECUTIVE OFFICER.SERES THERAPEUTICS - SHAFF HAS JOINED CO'S' BOARD AND WILL CONTINUE TO SERVE AS CO'S PRINCIPAL FINANCIAL OFFICER ON INTERIM BASIS.  Full Article

Seres Therapeutics Announces Initiation Of Ser-287 Phase 2B Eco-Reset Clinical Study For Ulcerative Colitis
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS ANNOUNCES INITIATION OF SER-287 PHASE 2B ECO-RESET CLINICAL STUDY FOR ULCERATIVE COLITIS.SERES THERAPEUTICS INC - COMPANY HAS RECEIVED $40 MILLION IN MILESTONE PAYMENTS WITH PHASE 2B STUDY START.SERES THERAPEUTICS - PHASE 2B STUDY IS 3-ARM PLACEBO-CONTROLLED TRIAL OF APPROXIMATELY 200 PATIENTS WITH ACTIVE MILD-TO-MODERATE ULCERATIVE COLITIS.  Full Article

Seres Therapeutics Reports Q3 Loss Per Share $0.54
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATES.Q3 LOSS PER SHARE $0.54.Q3 EARNINGS PER SHARE VIEW $-0.52 -- THOMSON REUTERS I/B/E/S.Q3 TOTAL REVENUE $9.1 MILLION VERSUS $23.0 MILLION LAST YEAR.  Full Article

Seres Therapeutics Qtrly Net Loss Of $29.0 Mln Vs $25.3 Mln
Thursday, 8 Mar 2018 

March 8 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.SERES THERAPEUTICS INC - QTRLY NET LOSS OF $29.0 MILLION VERSUS $25.3 MILLION.  Full Article

Seres Therapeutics Announces FDA Orphan Drug Designation For SER-287 In Treatment Of Pediatric Ulcerative Colitis
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR SER-287 IN TREATMENT OF PEDIATRIC ULCERATIVE COLITIS.SERES THERAPEUTICS INC - SER-287 PHASE 1B MICROBIOME DATA ARE EXPECTED IN EARLY 2018.  Full Article

Seres Therapeutics Q3 net loss per share ‍$0.17​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Seres Therapeutics Inc : :Seres Therapeutics reports third quarter 2017 financial results and provides update on operational progress.Seres Therapeutics - ‍positive results from SER-287 phase 1B study in mild-to-moderate ulcerative colitis; co to move program into further development​.Seres therapeutics Inc - ‍in early 2018, co anticipates results from SER-262 phase 1B study in primary C. Difficile infection​.Seres Therapeutics Inc qtrly net loss per share ‍$0.17​.Seres Therapeutics Inc qtrly ‍total revenue $23 million versus $13 million​.  Full Article

Seres Therapeutics reports positive topline results from ser-287 phase 1b study in patients with ulcerative colitis
Monday, 2 Oct 2017 

Oct 2 (Reuters) - Seres Therapeutics Inc ::Seres Therapeutics reports positive topline results from ser-287 phase 1b study in patients with ulcerative colitis.Seres Therapeutics Inc - ‍no clinically significant safety or tolerability findings were observed​.Seres - ‍ser-287 microbiome treatment resulted in a dose-dependent benefit in clinical remission rates, and an improvement in endoscopic scores​.  Full Article